Xbiome Revenue and Competitors

As the leading AI-based microbiome drug development company in China, Xbiome Co., Ltd. is dedicated to gut microbiome using AI techniques, and committed to the gut health of human being with medical treatments and precise and personalized management. The gut is the largest microbial ecosystem in the human body. It hosts about 100 trillion microbes – 500 – 1000 unique species, and contains 150-fold more genes than the human genome, which influence the human health systematically. Studies show that more than 50 human diseases are associated with dysbiosis of gut microbiota. Unlike the traditional paradigm of drug discovery, Xbiome's approach innovatively combines microbial technologies, artificial intelligence, bioinformatics analysis and gut microbiome technologies into a unique drug development platform, which substantially speeds up and improves the success rate of new drug development.